Table 2.
Clinical characteristics of all studies included in the meta-analysis.
| Authors | Mean age (years) | Duration of disease (months) | Nb of injections prior to conversion | Time between last anti-VEGF and conversion | Mean time of follow-up (months) | Mean number of aflibercept injections | Treatment regimen |
|---|---|---|---|---|---|---|---|
| Kumar [24] | 79 (IQR 72–84) |
44.7 (IQR 24–76) |
28.6 (IQR 10–47) |
34.4 days (IQR 32–37) | 6 | 5.6 (NS) | Loading then PRN |
| Bakall [25] | 79 (range 60–88) |
NS | 25.6 (6–74) | NS | 6 | 5.2 (4–6) | Loading then PRN |
| Gharbiya [26] | 70.1 (range 60–86) |
41.3 (15–58) | 34.4 (15–50) | 5.1 weeks (range 4–6) | 6 | 4.5 (3–6) | Loading then PRN |
| Messenger [27] | 80.3 (range 59–96) |
NS | 21.4 (4–60) | NS | 6, 12 | 7.2 (1–12) for 12 months NS at 6 months |
Loading then PRN |
| Wykoff [28] | 77.8 (range 55–95) |
NS | 42 (19–67) | 33 days (range 28–68) |
6 | 5.6 (4–6) | Loading then PRN |
| Chang [29] | 77.8 (NS) | 40 | 34.94 | NS | 6 | NS | Loading then bimonthly |
| Singh [30] | 78 (NS) | 14 | 9.62 (3–23) | 50 days (range 21–91) |
6 | NS | Loading then bimonthly |